基于分子结构优势,维拉苷酶α取得了卓越疗效。上述临床试验证据进一步证实了维拉苷酶α用于戈谢病患者的有效性和安全性,也为维拉苷酶α应用于国内临床实践提供了支持与保障。参考文献:[1]中国儿童戈谢病诊治专家共识(2021).[2]中国成人戈谢病诊治专家共识(2020).[3]Brumshtein B, Salinas P, Peterson B, et al. Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages[J]. Glycobiology. 2010 Jan;20(1):24-32.[4]Ben Turkia H, Gonzalez DE, Barton NW, et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease[J]. Am J Hematol. 2013 Mar;88(3):179-84.[5]VPRIV® (velaglucerase alfa). Summary of Product Characteristics. 2020.[6]Moran N. Shire's replacement enzymes validate gene activation[J]. Nat Biotechnol. 2010 Nov;28(11):1139-40.[7]Zimran A, Altarescu G, Philips M, et al. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience[J]. Blood. 2010 Jun 10;115(23):4651-6.[8]Zimran A, Elstein D, Gonzalez DE, et al. Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials[J]. Blood Cells Mol Dis. 2018 Feb;68:153-159.[9]Biegstraaten M, et al. Blood Cells Mol Dis 2018;68: 203–208.[10]Zimran A, Pastores GM, Tylki-Szymanska A, et al. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase[J]. Am J Hematol. 2013 Mar;88(3):172-8.[11]Elstein D, Mehta A, Hughes DA, et al. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease[J]. Am J Hematol. 2015 Jul;90(7):592-7.[12]Elstein D, Altarescu G, Maayan H, et al. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem[J]. Blood Cells Mol Dis. 2012 Jan 15;48(1):45-50.[13]Smith L, Rhead W, Charrow J, et al. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase[J]. Mol Genet Metab. 2016 Feb;117(2):164-71.[14]Pastores GM, Rosenbloom B, Weinreb N, et al. A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability[J]. Genet Med. 2014 May;16(5):359-66.[15]VPRIV ® PRESCRIBING INFORMATION. Revised: 12/2020.